Mantle Cell Lymphoma - Pipeline Review, H1 2016 - Product Image

Mantle Cell Lymphoma - Pipeline Review, H1 2016

  • ID: 3643176
  • Report
  • 426 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • Bayer AG
  • Genentech, Inc.
  • Incyte Corporation
  • MedImmune, LLC
  • Pfizer Inc.
  • MORE
Mantle Cell Lymphoma - Pipeline Review, H1 2016

Summary

The report ‘Mantle Cell Lymphoma - Pipeline Review, H1 2016’, provides an overview of the Mantle Cell Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Mantle Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mantle Cell Lymphoma and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mantle Cell Lymphoma
- The report reviews pipeline therapeutics for Mantle Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Mantle Cell Lymphoma therapeutics and enlists all their major and minor projects
- The report assesses Mantle Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Mantle Cell Lymphoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Mantle Cell Lymphoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mantle Cell Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • Bayer AG
  • Genentech, Inc.
  • Incyte Corporation
  • MedImmune, LLC
  • Pfizer Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Mantle Cell Lymphoma Overview

Therapeutics Development

Pipeline Products for Mantle Cell Lymphoma - Overview

Pipeline Products for Mantle Cell Lymphoma - Comparative Analysis

Mantle Cell Lymphoma - Therapeutics under Development by Companies

Mantle Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes

Mantle Cell Lymphoma - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Mantle Cell Lymphoma - Products under Development by Companies

Mantle Cell Lymphoma - Products under Investigation by Universities/Institutes

Mantle Cell Lymphoma - Companies Involved in Therapeutics Development

AB Science SA

AbbVie Inc.

Acetylon Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

Affimed Therapeutics AG

Amgen Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

Bayer AG

Bristol-Myers Squibb Company

Celgene Corporation

Cellular Biomedicine Group, Inc.

Eisai Co., Ltd.

EpiZyme, Inc.

Fate Therapeutics, Inc.

Genentech, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Hutchison MediPharma Limited

ImmunoGen, Inc.

Immunomedics, Inc.

Incyte Corporation

Inflection Biosciences Limited

Johnson & Johnson

Juno Therapeutics Inc.

Karyopharm Therapeutics, Inc.

Kite Pharma, Inc.

Les Laboratoires Servier SAS

LFB S.A.

MedImmune, LLC

Merck & Co., Inc.

Millennium Pharmaceuticals, Inc.

MorphoSys AG

Nordic Nanovector ASA

Novartis AG

Onconova Therapeutics, Inc.

Onyx Pharmaceuticals, Inc.

Pfizer Inc.

Pharmacyclics, Inc.

Portola Pharmaceuticals, Inc.

Seattle Genetics, Inc.

Selvita S.A.

Sorrento Therapeutics, Inc.

Stemline Therapeutics, Inc.

Takeda Pharmaceutical Company Limited

TG Therapeutics, Inc.

Mantle Cell Lymphoma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(INCB-039110 + INCB-040093) - Drug Profile

13197 - Drug Profile

AB-8779 - Drug Profile

abexinostat hydrochloride - Drug Profile

acalabrutinib - Drug Profile

acalisib - Drug Profile

ACY-241 - Drug Profile

ACY-775 - Drug Profile

AFM-11 - Drug Profile

agatolimod sodium - Drug Profile

alisertib - Drug Profile

AMG-319 - Drug Profile

ASN-002 - Drug Profile

AT-7519 - Drug Profile

avicin d - Drug Profile

bendamustine hydrochloride - Drug Profile

Betalutin - Drug Profile

BGB-3111 - Drug Profile

BLyS-gel - Drug Profile

BMS-986016 - Drug Profile

buparlisib hydrochloride - Drug Profile

carfilzomib - Drug Profile

CBM-C19.1 - Drug Profile

CBM-C20.1 - Drug Profile

CC-122 - Drug Profile

Cellular Immunotherapy for Oncology - Drug Profile

Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile

Cellular Immunotherapy to Target ROR1 for Oncology - Drug Profile

cerdulatinib - Drug Profile

copanlisib hydrochloride - Drug Profile

daratumumab - Drug Profile

denintuzumab mafodotin - Drug Profile

E-7449 - Drug Profile

entospletinib - Drug Profile

epratuzumab - Drug Profile

EPZ-015666 - Drug Profile

FT-1050 - Drug Profile

HMPL-523 - Drug Profile

IBL-301 - Drug Profile

ibrutinib - Drug Profile

idelalisib - Drug Profile

IGN-002 - Drug Profile

IMGN-529 - Drug Profile

IMMU-114 - Drug Profile

INA-01 - Drug Profile

INCB-40093 - Drug Profile

inebilizumab - Drug Profile

inebilizumab + MEDI-0680 - Drug Profile

inebilizumab + rituximab - Drug Profile

itacitinib adipate - Drug Profile

ixazomib citrate - Drug Profile

JCAR-014 - Drug Profile

JCAR-015 - Drug Profile

JCAR-017 - Drug Profile

JNJ-64052781 - Drug Profile

KTEC-19 - Drug Profile

LAM-002A - Drug Profile

lenalidomide - Drug Profile

Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile

Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile

MOR-208 - Drug Profile

ON-123300 - Drug Profile

ONC-201 - Drug Profile

OSU-2S - Drug Profile

pembrolizumab - Drug Profile

polatuzumab vedotin - Drug Profile

ribociclib - Drug Profile

S-055746 - Drug Profile

SEL-120 - Drug Profile

SEL-12034 - Drug Profile

SEL-24B489 - Drug Profile

selinexor - Drug Profile

SGN-CD70A - Drug Profile

SL-101 - Drug Profile

TAK-659 - Drug Profile

temsirolimus - Drug Profile

TGR-1202 - Drug Profile

tisagenlecleucel-T - Drug Profile

tretinoin - Drug Profile

ublituximab - Drug Profile

venetoclax - Drug Profile

vorinostat - Drug Profile

Mantle Cell Lymphoma - Recent Pipeline Updates

Mantle Cell Lymphoma - Dormant Projects

Mantle Cell Lymphoma - Discontinued Products

Mantle Cell Lymphoma - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Mantle Cell Lymphoma, H1 2016

Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Investigation by Universities/Institutes, H1 2016

Mantle Cell Lymphoma - Pipeline by AB Science SA, H1 2016

Mantle Cell Lymphoma - Pipeline by AbbVie Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2016

Mantle Cell Lymphoma - Pipeline by Amgen Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Bayer AG, H1 2016

Mantle Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016

Mantle Cell Lymphoma - Pipeline by Celgene Corporation, H1 2016

Mantle Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016

Mantle Cell Lymphoma - Pipeline by EpiZyme, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Fate Therapeutics, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Genentech, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2016

Mantle Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H1 2016

Mantle Cell Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Immunomedics, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Incyte Corporation, H1 2016

Mantle Cell Lymphoma - Pipeline by Inflection Biosciences Limited, H1 2016

Mantle Cell Lymphoma - Pipeline by Johnson & Johnson, H1 2016

Mantle Cell Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Les Laboratoires Servier SAS, H1 2016

Mantle Cell Lymphoma - Pipeline by LFB S.A., H1 2016

Mantle Cell Lymphoma - Pipeline by MedImmune, LLC, H1 2016

Mantle Cell Lymphoma - Pipeline by Merck & Co., Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by MorphoSys AG, H1 2016

Mantle Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016

Mantle Cell Lymphoma - Pipeline by Novartis AG, H1 2016

Mantle Cell Lymphoma - Pipeline by Onconova Therapeutics, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Pfizer Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Selvita S.A., H1 2016

Mantle Cell Lymphoma - Pipeline by Sorrento Therapeutics, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2016

Mantle Cell Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016

Mantle Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Mantle Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016

Mantle Cell Lymphoma - Dormant Projects, H1 2016

Mantle Cell Lymphoma - Dormant Projects (Contd..1), H1 2016

Mantle Cell Lymphoma - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Mantle Cell Lymphoma, H1 2016

Number of Products under Development for Mantle Cell Lymphoma - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AB Science SA
AbbVie Inc.
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
Affimed Therapeutics AG
Amgen Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
Bayer AG
Bristol-Myers Squibb Company
Celgene Corporation
Cellular Biomedicine Group, Inc.
Eisai Co., Ltd.
EpiZyme, Inc.
Fate Therapeutics, Inc.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
ImmunoGen, Inc.
Immunomedics, Inc.
Incyte Corporation
Inflection Biosciences Limited
Johnson & Johnson
Juno Therapeutics Inc.
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
Les Laboratoires Servier SAS
LFB S.A.
MedImmune, LLC
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
MorphoSys AG
Nordic Nanovector ASA
Novartis AG
Onconova Therapeutics, Inc.
Onyx Pharmaceuticals, Inc.
Pfizer Inc.
Pharmacyclics, Inc.
Portola Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Selvita S.A.
Sorrento Therapeutics, Inc.
Stemline Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
TG Therapeutics, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll